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Abstract
Background: Several studies have demonstrated the efficacy of artemisinin-combination therapy (ACT) across
malaria zones of the world. Fixed dose ACT with shorter courses and fewer tablets may be key determinants to
ease of administration and compliance.
Methods: Children aged one year to 13 years presenting with uncomplicated Plasmodium falciparum malaria were
recruited in Ibadan, south-western Nigeria. A total of 250 children each were randomly assigned to receive three
doses of artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP) (12 hourly doses over 24 hours) or three
doses of artesunate/amodiaquine (AS + AQ) (daily doses over 48 hours). Efficacy and safety of the two drugs were
assessed using a 28-day follow-up and the primary outcome was PCR- corrected parasitological cure rate and
clinical response.
Results: There were two (0.4%) early treatment failures, one in each treatment arm. The PCR corrected cure rates
for day 28 was 97.9% in the AS + AQ arm and 95.6% in the AS + SMP arm (p = 0.15). The re-infection rate was
1.7% in the AS + AQ arm and 5.7% in the AS + SMP arm (p = 0.021). The fever clearance time was similar in the
two treatment groups: 1 - 2 days for both AS + SMP and AS + AQ (p = 0.271). The parasite clearance time was
also similar in the two treatment groups with 1 - 7 days for AS + SMP and 1 - 4 days for AS + AQ (p = 0.941). The
proportion of children with gametocytes over the follow-up period was similar in both treatment groups. Serious
Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume,
liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume
was significantly lower in the AS + SMP group.
Conclusions: This study demonstrates that AS + SMP FDC given as three doses over 24 hours (12-hour intervals)
has similar efficacy as AS + AQ FDC given as three doses over 48 hours (24-hour interval) for the treatment of
uncomplicated Plasmodium falciparum malaria in children in Nigeria. Both drugs also proved to be safe. Therefore,
AS + SMP could be an alternative to currently recommended first-line ACT with continuous resistance surveillance.
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In Nigeria, nearly 110 million of clinical cases of malaria
are diagnosed per year, translating into about 50% of
the adult population experiencing at least one malaria
episode per year, while young children can have up to
two to four attacks of malaria annually [1]. In addition
to the direct health impact of malaria on the Nigerian
population, the economic loss linked to malaria in this
country is estimated to ~132 billion Naira (±878 million
USD) per year. In order to combat this devastating
situation, the Nigerian authorities developed in 1996 a
first National Malaria Control Policy, and in 1999 the
Roll Back Malaria (RBM) programme was initiated.
National drug efficacy trials conducted in 2002 in
Nigeria demonstrated that the first line treatments then
employed, chloroquine and sulphadoxine/pyrimethamine
(SP) were no longer adequate and in 2005, the highly
efficacious artemisinin-based combination therapy
(ACT) was introduced in the country [1]. Artemether-
lumefantrine was elected first-line treatment for uncom-
plicated malaria with artesunate-amodiaquine (AS +
AQ) recommended as an alternative [2]. Nowadays, SP
is not recommended for the treatment of uncomplicated
malaria due to its high resistance which can be as high
as 35% but it is still in use for intermittent preventive
therapy (IPT) in pregnant women. Similarity in the
structure of SP and SMP denotes a potential for cross
resistance [1,2].
Although the use of ACT for the treatment of uncom-
plicated malaria has been introduced several years ago,
its utilization in the field is still below expected levels.
The reasons explaining this situation include the poor
availability and/or relatively high cost of ACT on the
African market. One of the key elements of the RBM
strategy is that malaria patients should have access to
appropriate and adequate treatment within 24 hours of
the onset of symptoms [1,2]. An anti-malarial drug to
be used at home must, therefore, be safe, effective,
affordable, easy to administer and preferably available in
as i n g l ed o s ep a c k a g e .F o l l o w i ng these lines, fixed-dose
combinations (FDC) are preferred to co-blistered drugs
as they prevent inadequate dosing (preventing drug
resistance) and contribute to increase treatment
compliance.
I nv i e wo ft h ei d e a lp r o f i l et ob ef o u n di na na n t i -
malarial drug, the combination of artesunate and sul-
phamethoxypyrazine/pyrimethamine (AS + SMP) repre-
sents an interesting treatment option in case first-line
drugs are not readily available. In fact, this product is
easy to use, safe, and has previously demonstrated high
efficacy in several endemic areas whether it is taken
under a 24- or 48- hour regimen [3-5]. Previously
offered as a co-blistered drug [6,7], the AS + SMP
combination is now available as a FDC, which can easily
be taken by malaria patients (three tablets only). In
addition, since the SMP component has broad-spectrum
anti-microbial activity, it also presents the interesting
advantage of offering ancillary benefits against infections
that may have been wrongly diagnosed as malaria [8,9].
In order to evaluate the safety and efficacy of the 24-
hour therapy of AS + SMP FDC in south-west Nigeria,
a cohort of children suffering from uncomplicated
malaria were treated either with this ACT, or with a 48-
hour therapy of AS + AQ FDC.
Methods
Study site
This study was conducted at the University College
Hospital and at the Oni Memorial Children’sH o s p i t a l
both located in the urban areas of Ibadan, Oyo State,
Nigeria. The intensity of malaria transmission varies
considerably throughout Nigeria. Ibadan is located in
the forest savannah woodland zone with average rainfall
of 975 - 1474 mm/year [10]. Malaria, mainly caused by
Plasmodium falciparum, is endemic in the region with a
six-month transmission season (May-October) reaching
its peak in August [11]. The overall entomological
inoculation rates for Anopheles gambiae s.l.r a n g ef r o m
18 to 145 infective bites per person per year [2]. Specifi-
cally in south-west Nigeria, the reported seasonal (six-
month) entomological inoculation rates were 128.7 in
2001 and 131.3 in 2002 [11].
This study was approved by the Joint Ethics Commit-
tee of University of Ibadan and University College Hos-
pital, Ibadan, Nigeria. The study was conducted in
accordance with all requirements of the ICH Guidelines
for Good Clinical Practice as well as the requirements
of the Declaration of Helsinki. Clinical trial approval
was obtained from the National Agency for Food and
Drug Administration and Control in Nigeria (NAF-
DAC). Written informed consent was obtained from all
parents or guardians of eligible children prior to
enrolment.
Patient screening and recruitment
Children presenting to each of the two study sites were
screened for eligibility and invited to participate in the
study if they met the following inclusion criteria: aged
between 1 and 13 years; body weight between 6 and 40
kg; history of fever in the previous 24 hours or mea-
sured fever (axillary temperature >37.5°C); mono-infec-
tion with P. falciparum, with parasitaemia in the range
of 2,000-200,000 asexual parasites per microlitre of
blood; and no general danger signs or signs of severe
and complicated falciparum malaria as per WHO guide-
lines [12].
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A randomized, controlled, open-label trial design was
used. Assuming a proportion of 94% patients cured
(with PCR-corrected cure rate at day 28 as primary end-
point) with AS + SMP, an equal proportion of patients
cured with AS + AQ, a sample of 250 patients (taking
into account 10-15% loss to follow-up) was required in
each treatment arm to detect the 6% difference in para-
sitological cure rates with a power of 80% (a =0 . 0 2 5
one-sided). Sample size calculations were done using
nQuery Advisor 5.0. The randomization code was com-
puter-generated with stratification per treatment centre,
from which treatment groups were assigned.
At enrolment, a physical examination was performed,
weight and axillary temperatures recorded and a medical
history was obtained from parents/guardians including
presenting symptoms and current medication. A finger
prick blood sample was obtained for thin and thick
blood smears and blotted on filter paper for parasite
genotyping. A blood sample was also obtained for
assessment of haematological and biochemical
parameters.
E l i g i b l ec h i l d r e nw e r et h e na s s i g n e di n t oo n eo ft h e
two treatment groups according to the randomization
code. The treatments were given in the clinic by the
recruiting physician. One group received three doses of
artesunate/amodiaquine 100/206.2 mg tablets (Amo-
nate
®, Dafra Pharma ltd., Kenya), crushed mixed with
clean water and administered at 0, 24 and 48 hours.
The second group received artesunate/sulphamethoxy-
pyrazine/pyrimethamine 100/250/12.5 mg tablets (Co-
Arinate FDC
® Junior, Dafra Pharma Ltd., Kenya),
crushed, mixed with water and administered at 0, 12
and 24 hours. Treatment doses were given based on the
age of the patient: children under 7 years received 1/2
tablet per dose (50/153.1 mg As/AQ and 50/125/6.25
mg As/SM/P) while children aged 7 years and older
received a full tablet per dose. They were then observed
for 1 hour after drug administration for vomiting. If
vomiting occurred within 30 min after administration,
the full treatment dose was re-administered. If vomiting
occurred between 30-60 min after administration, half
the treatment dose was re-administered.
No prior therapy was given and the only concomitant
therapy administered were antipyretic drugs in patients
with temperatures ≥38.5°C.
Follow-up
The children on 12 hourly regimen whose second dose
fell at night were admitted for the treatment to be given
by the nurses on duty to ensure treatment compliance.
Clinical and parasitological evaluation (thin and thick
smears) was done on each day of follow-up (days 1, 2, 3,
7, 14, 21 and 28), or on any other day if the child was
feeling sick. Patients were called back on these days or
visited at home. During each visit, a brief clinical history
was obtained to assess new complaints and possible side
effects and a physical examination was performed. The
haemogram and biochemical analysis (bilirubin, creati-
nine and liver enzymes AST, ALT) were done on days
0, 7 and 14 to detect possible significant abnormalities.
Filter paper blood samples for parasite genotyping were
obtained on day 28 or earlier if presented with repeat of
the symptoms. Patients were excluded from the study if
they withdrew consent, left the study area or reported
taking anti-malarial medication during the follow-up
period.
Response to drug treatment was assessed using modi-
fied WHO clinical classification system: all patients were
not febrile at presentation, hence a temperature < 37.5°
C was not an exclusion criterion and patients were fol-
lowed up for 28 days in this area of intense transmis-
sion. The clinical classification system consisted of
adequate clinical and parasitological response (ACPR),
late parasitological failure (LPF), late clinical failure
(LCF) and early treatment failure (ETF). The cure rates
o nd a y2 8w e r ea d j u s t e do nt h eb a s i so ft h eP C Rg e n o -
typing results of paired samples for patients with recur-
rent parasitaemia after day 14 of starting treatment.
Laboratory evaluation
A finger prick blood sample was taken to prepare thick
and thin blood smears on days 0, 1, 2, 3, 7, 14, 21, 28
and on any other (unscheduled) visit. The slides were
air dried, stained with 10% Giemsa for 20 min and read
independently by two technicians. Parasite density (the
number of parasites and gametocytes per μl) was calcu-
lated by counting parasites against 200 leukocytes and
assuming a leukocyte count of 6,000/μl of blood. A slide
was considered negative after reading at least 200 power
fields. Thin blood smears were specifically used to iden-
tify Plasmodium parasite species. All qualitative discor-
dant slides and slides with a parasite density difference
≥50% were read by a third microscopist. For quality
control 10% of randomly selected slides were reread by
an independent microscopist, not involved in the study.
Filter paper blood spots were collected on days 0, 28
or any other day of recurrent parasitaemia. Genotypes
of the parasite population in each sample collected from
patients with microscopically confirmed P. falciparum
infections at enrollment, and during follow-up if the
patients were parasitaemic on or before D28 were deter-
mined using PCR techniques. Analysis of genetic poly-
morphisms was performed on paired primary and post-
treatment parasites samples obtained from the two
treatment groups. Paired primary and post-treatment
parasites were analysed using parasite loci that exhibit
repeated numbers of polymorphisms to distinguish true
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of MSP-1 (merozoite surface proteins-1), and the Block
3o fMSP-2 (merozoite surface protein-2) and region II
of GLURP were amplified by two rounds of PCR using
primers and amplification conditions [12,13].
Ten microliters of the PCR products were resolved by
electrophoresis on a 2% agarose gel and sized against a
100-base pair molecular weight marker (New England
Biolabs, Beverly, MA). The banding pattern of the post-
treatment parasites were compared with matched
primary parasites. Post-treatment and primary infection
parasites showing identical bands were considered as
true treatment failure, while non-identity will indicate a
new infection [13,14]. Patients failing treatment within
28 days were retreated with oral quinine and were
regarded as recrudescence or re-infection.
Statistical analysis
The case report forms were double checked to ensure
complete and accurate data collection. Dual data entry
was done by two clerks after which data was compared,
corrected and validated by the data manager. Data ana-
lysis was done using Epi Info version 6 and SPSS version
11. The primary analysis was a non-inferiority analysis
(with clinically relevant difference of 6% and one-sided
significance level of a = 0.025) based on PCR-corrected
adequate clinical and parasitological response (ACPR)
on day 28 as primary efficacy endpoint [15]. Secondary
3500 
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Not meeting inclusion criteria
(n=2730)
Refused to participate
(n=60)
Other reasons
(n=10)
500
Randomization
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Allocated to AS + SMP
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Lost to follow-up
12
Lost to follow-up
229
Analyzed
238
Analyzed
Did not receive allocated
intervention (n=0)
Allocation
Follow-up
Analysis
Figure 1 Trial profile.
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site clearance time and packed cell volume levels. Chi-
square and Fisher exact or Yate’s correction tests were
used to compare proportions between treatment groups.
Normally distributed continuous variables were com-
pared using Student’s t test between two independent
groups while non-parametric tests (Wilcoxon rank-sum)
were used to analyse skewed data. Kaplan Meier was
used to analyse the significance between the rates of re-
infection in the two treatment arms. Two tailed p-values
<0.05 were considered statistically significant. The Inten-
tion-To-Treat (ITT) population including all patients
w h ow e r er a n d o m i z e dt oe i t h e ro ft h et w ot r e a t m e n t
groups and received at least one dose of study medica-
tion was used for safety analysis. The Per-Protocol
population (PP) including all patients that received
treatment and were not lost to follow-up was used for
the efficacy analysis.
Results
Patients characteristics
Out of 3,500 children screened for malaria, 500 were
enrolled into the trial; 250 were assigned to the AS +
AQ treatment arm and 250 to the AS + SMP arm (Fig-
ure 1). Thirty three children (6.6%) were lost to follow-
up, of which 21 in the AS + SMP arm and 12 in the AS
+ AQ arm. Both treatment groups were comparable in
terms of baseline demographic, clinical, parasitological
and laboratory characteristics (Table 1).
Parasitological cure rates
There were two early treatment failures, one in each
treatment arm (0.4%). The PCR corrected cure rates for
day 28 was 97.9% in the AS + AQ arm and 95.6% in the
AS + SMP arm (p = 0.15). The re-infection rate was
1.7% in the AS + AQ arm and 5.7% in the AS + SMP
arm (Table 2, 3 and Additional file 1) (p = 0.021).
Fever, parasite and gametocyte clearance and anaemia
The median fever clearance time was similar in the two
treatment groups: 1 day for both AS + SMP and AS +
AQ (p = 0.271). The median parasite clearance time was
also similar in the two treatment groups with a range of
1 - 7 days for AS + SMP and 1 - 3 days for AS + AQ
(p = 0.941). The proportions of children with gameto-
cytes over the follow-up period were similar in both
treatment groups. Sixteen children in each treatment
arm had gametocytes on day 0 (7.0% for AS + SMP and
6.7% for AS + AQ) (Table 2). On day 28, the proportion
of children with gametocytes was reduced to 2.2% for
AS + SMP and 3.4% for AS + AQ (p = 0.408) (Figure
2). On day 14, the proportion of children with anaemia
was reduced to 1.3% both in AS + SMP and AS + AQ
treatment group (Figure 3).
Adverse events
Serious adverse events were not reported in any of the
patients. There was no significant difference in the pro-
portions of patients reporting adverse events in the two
Table 1 Enrollment characteristics of children with
uncomplicated malaria (ITT)
Characteristics AS + SMP
(n = 250)
AS + AQ
(n = 250)
p-value
Sex (M:F) 128:122 136:114 0.299
Age (months)
Mean ± SD 61.88 ± 38.139 60.77 ± 35.93 0.739
Range 12 - 156 12 - 156
Proportion
With age < 5 years 49.2% 58.8% 0.031
Weight
Mean ± SD 17.51 ± 7.01 17.29 ±6.90 0.729
Range 6 - 40 7 - 40
Temperature (Day 0)
Mean ± SD 37.91 ± 1.15 37.83 ± 1.17 0.441
Range 35.5 - 40.5 35.3 - 40.7
Parasite Density (Day 0)
Median 15549.00 11673.50 0.078
Range 2009 - 199950 2020 - 199200
PCV* (Day 0)
Mean ± SD 29.79 ± 5.18 29.94 ± 5.09 0.748
Range 12 - 42 12 - 41
AST* (Day 0)
Mean ± SD 38.76 ± 14.66 38.88 ± 15.54 0.929
Range 10 - 95 10 - 101
ALT* (Day 0)
Mean ± SD 31.10 ± 16.63 30.27 ± 15.29 0.559
Range 10 - 99 10 - 91
CRT* (Day 0)
Mean ± SD 0.56 ± 0.26 0.56 ± 0.24 0.860
Range 0.20 - 1.30 0.20 - 1.20
Total Bilirubin (Day 0)
Mean ± SD 0.58 ± 0.28 0.62 ± 0.27 0.191
Range 0.10 - 1.70 0.10 - 1.30
WBC (Day 0)
Median 7450.00 7500.00 0.735
Range 1200 - 38000 1300 - 24600
PCV = packed cell volume; AST = aspartate aminotransferase; ALT = alanine
aminotransferase; CRT = creatinine
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AQ reported one or more of the following adverse
events: vomiting (n = 1), excessive sleepiness (n = 2),
abdominal pain (n = 1), and weakness (n = 3). Three
patients (1.3%) treated with AS + SMP reported vomit-
ing, one of these patients also reported nausea as
adverse event. None of these patients needed to be
admitted as a result of these events. For all children,
laboratory values (packed cell volume, liver enzymes,
bilirubin) remained within normal levels during the fol-
low-up period (Table 4).
Discussion
This study is documenting the efficacy and tolerability
of AS + SMP compared to the recommended artesu-
nate-amodiaquine (AS + AQ) ACT for the treatment of
uncomplicated P. falciparum m a l a r i ai nc h i l d r e ni na n
endemic area of south-western Nigeria. The study was
based on a 28-day follow-up period.
Many African countries have adopted artemisinin
based combination therapies (ACTs) as first-line therapy
against uncomplicated malaria, particularly artemether-
lumefantrine (AL) and AS + AQ. However based on
field experience, there is a need to assess other forms of
ACT in order to identify a suitable alternative to recom-
mended treatments in case those are not readily avail-
able to the patients who urgently need to be treated.
The 28-day cure rates observed in this study were 95.6%
in the AS + SMP treatment arm compared to 97.9% in
the AS + AQ treatment arm (p = 0.151) suggesting that
the therapeutic efficacy of both drugs were similar.
These findings are in agreement with previously
reported studies on AS + SMP from other endemic and
non-endemic malaria areas [3-7]. The observed AS +
AQ cure rate is also similar to those stated in other stu-
dies [16-18]. The significantly higher under 5 year old
children in the AS + AQ group would have possibly led
to a lower inability to clear malarial parasites in the AS
+ AQ group as a result of their relatively low immunity.
Table 2 Therapeutic response (PP)
Characteristics AS + SMP
(n = 229)
AS + AQ
(n = 238)
p-value
Fever clearance time (Days)
Median (Range) 1.00 (1 - 2) 1.00 (1 - 2) 0.271
Parasite clearance time (Days)
Median (Range) 1.00 (1 - 7) 1.00 (1 - 3) 0.941
Proportion with Fever
Day 1 32 (12.9%) 16 (6.5%) 0.016
Day 2 5 (2.0%) 5 (2.0%) -
Day 3 3 (1.2%) 3 (1.2%) -
Proportion with Parasite
Day 1 66 (28.8%) 70 (29.4%) 0.888
Day 2 12 (5.3%) 9 (3.8%) 0.441
Day 3 3 (1.3%) 0 (0.0%) 0.117
+
Proportion with Gametocyte
Day 0 16 (7.0%) 16 (6.7%) 0.910
Day 1 18 (7.9%) 15 (6.3%) 0.511
Day 2 17 (7.4%) 18 (7.6%) 0.954
Day 3 17 (7.4%) 13 (5.5%) 0.387
Day 7 13 (5.7%) 11 (4.7%) 0.636
Day 14 8 (3.5%) 5 (2.2%) 0.390
Day 21 2 (0.9%) 3 (1.3%) 0.660
Day 28 5 (2.2%) 8 (3.5%) 0.408
Treatment outcome
ACPR* 219 (95.6%) 233 (97.9%) 0.151
Recrudescence 9 (3.9%) 4 (1.7%) 0.135
Re-infection++ 13 (5.7%) 4 (1.7%) 0.021
ETF* 1 (0.4%) 1 (0.4%) -
Fisher’s
+
*ACPR = adequate parasitological and clinical response; ETF = early treatment
failure
++ Kaplan Meier
Table 3 Survival Characteristics of re-infection in the treatment groups
Group Number of cases Number of events Number censored Mean survival time in days (95% C.I)
AS/SMP 229 13 216(94.3%) 27.541 (27.249-27.834)
AS/AQ 238 4 234(98.3%) 27.882 (27.695-28.070)
Figure 2 Proportion of children with gametocytes up to 28
days after treatment with AS + SMP or AS +AQ. The number of
gametocytes per μl was calculated by counting parasites against
200 leukocytes (thick blood smear) and assuming a leukocyte count
of 6,000/μl of blood.
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in the AS + SMP group than the AS + AQ group (21
versus 12) this may not be related to the drug efficacy
as these losses were mainly due to movement to and
from schools as well as other family social issues. The
fact that 3,500 children had to be screened in order to
attain the postulated sample size of 250 children per
treatment arm suggests that a high proportion of the
cases of fever in children are not due to malaria
infection, but e.g. due to bacterial infections [9]. On the
field, in the absence of parasitological confirmation, the
anti-microbial profile of the SMP component of AS +
SMP would have provided clinical benefits to such chil-
dren even if malaria would have been wrongly
diagnosed.
Gametocyte carriage before and following treatment
were similar in the two treatment arms, which is
expected to be the result of the action of artesunate
[19]. Interestingly, sulphadoxine/pyrimethamine (SP)
was shown to increase gametocyte carriage following
treatment of uncomplicated malaria infection [20], but
this does not seem to be the case for SMP. In fact,
Sowunmi et al reported that, despite slower clearance of
sexual parasitaemia in children treated with AQ + SMP
compared with those treated with AL, treatment with
the former was not associated with increased gameto-
cyte carriage [19].
Both AS + SMP and AS + AQ treatments were well tol-
erated and the frequency of reported adverse events was
similar in the two treatment arms. In reality, the reported
adverse events were difficult to distinguish from signs and
symptoms of malaria. It is notable that the reported fre-
quency of those with itching treated with AS + AQ was
low, similar to what was previously reported by Sowunmi
et al in 1989 [21]. Serious adverse events such as icterus
or intravascular haemolysis were not reported by any of
Figure 3 Proportion of children with anaemia up to 14 days
after treatment with AS + SMP or AS + AQ.
Table 4 Haematological and biochemical parameters (ITT)
Drug type Day 0 Day 7 Day 14
Total bilirubin
Mean ± SD AS + SMP 0.58 ± 0.28 0.58 ± 0.28 0.53 ± 0.27
AS + AQ 0.62 ± 0.27 0.59 ± 0.26 0.53 ± 0.27
p-value 0.191 0.718 0.982
PCV*
Mean ± SD AS + SMP 29.79 ± 5.18 30.69 ± 4.50 33.65 ± 4.07
AS + AQ 29.94 ± 5.09 31.78 ± 4.39 34.96 ± 4.32
p-value 0.748 0.008 0.001
AST*
Mean ± SD AS + SMP 38.76 ± 14.66 37.79 ± 15.59 36.90 ± 13.71
AS + AQ 38.88 ± 15.54 36.82 ± 15.26 36.41 ± 13.85
p-value 0.929 0.492 0.700
ALT*
Mean ± SD AS + SMP 31.10 ± 16.63 31.27 ± 15.50 29.93 ± 15.38
AS + AQ 30.27 ± 15.29 30.04 ± 14.43 29.09 ± 14.68
p-value 0.559 0.365 0.545
CRT*
Mean ± SD AS + SMP 0.56 ± 0.26 0.55 ± 0.28 0.54 ± 0.27
AS + AQ 0.55 ± 0.24 0.55 ± 0.25 0.53 ± 0.24
p-value 0.860 0.810 0.745
￿ PCV = packed cell volume; AST = aspartate aminotransferase; ALT = alanine aminotransferase;
￿ CRT = creatinine
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up was found to be significantly lower in patients treated
with AS + SMP and this may be related to high frequency
(23.9% in males and 4.6% in females) of glucose six phos-
phate dehydrogenase (G6PD) deficiency in the study area
[22]. This would have been substantiated if all patients
were screened for G6PD Deficiency.
In summary, this study demonstrates that AS + SMP
FDC given as three doses over 24 hours (12-hour inter-
vals) has similar efficacy as AS + AQ FDC given as
three doses over 48 hours (24-hour interval) in terms of
fever and parasite clearance for the treatment of uncom-
plicated Plasmodium falciparum malaria in children in
Nigeria. Both drugs also proved to be safe though AS +
SMP has a higher re-infection rate. AS + SMP repre-
sents a good alternative to recommended first line treat-
ments in areas where these are not available, or only
offered at high costs. A continuous surveillance on the
development of drug resistance is however essential as a
result of potential cross resistance between SP and SMP.
Additional material
Additional file 1: Kaplan Meier curve for rates of re-infection in the
treatment arms AS+SMP and AS+AQ.
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